BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel
Draws on a Deep Background at Leading Life Sciences Companies
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 7, 2017--
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced the appointment of Stephana Patton, Ph.D.,
J.D., as General Counsel, a newly created position.
Reporting in her new role to Adi Mohanty, Co-CEO, Dr. Patton will
oversee all legal matters at the company.
“I am pleased to welcome Stephana to BioTime at this important time,”
stated Mr. Mohanty. “She brings a breadth and depth of legal experience
and expertise in the biopharmaceutical industry and will make important
contributions as we continue to simplify our corporate structure,
advance our clinical development programs, report additional human data,
leverage our sizeable intellectual property portfolio, and prepare for
commercialization.”
Dr. Patton brings more than 17 years of experience creating portfolio
value at publicly-traded biotechnology and pharmaceutical companies. Dr.
Patton was formerly the General Counsel and Commercial Compliance
Officer at BioDelivery Sciences, a publicly-traded specialty
pharmaceutical company. Prior to BioDelivery Sciences, she held various
senior management positions, including leading Intellectual Property
(IP) and Licensing at Salix Pharmaceuticals, a global pharmaceutical
company that was acquired for $11.2 Billion in 2015. Prior to joining
Salix, Dr. Patton was in private practice at a large international law
firm known for its IP and corporate securities practices. Her practice
focused on counseling clients on IP-related matters as well as licensing
transactions for biotechnology and pharmaceutical companies at varying
stages of product development. Dr. Patton earned a Juris Doctor (J.D.)
degree from the Boston University School of Law and a Ph.D. in
Biochemistry, Cell and Developmental Biology from Emory University.
“I am thrilled to join the outstanding team at BioTime,” said Dr.
Patton. “The company is well positioned with exciting clinical programs
in aesthetics and ophthalmology that address multi-billion dollar global
market opportunities. I look forward to working with the entire team to
drive our continued success.”
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells. Pluripotent cells are capable of becoming
any of the cell types in the human body. Pluripotent cells have
potential application in many areas of medicine with large unmet patient
needs, including various age-related degenerative diseases and
degenerative conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.
Forward-Looking Statements
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for BioTime, Inc. and its
subsidiaries, along with other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the business of BioTime, Inc. and its
subsidiaries, particularly those mentioned in the cautionary statements
found in more detail in the “Risk Factors” section of its Annual Reports
on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC
(copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. BioTime, Inc. specifically disclaims any
obligation or intention to update or revise these forward-looking
statements as a result of changed events or circumstances that occur
after the date of this release, except as required by applicable law.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
LinkedIn,
Facebook,
YouTube,
and Google+.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170207005521/en/
Source: BioTime, Inc.
Investor Contact:
EVC Group, Inc.
Matt Haines,
917-733-9297
mhaines@evcgroup.com
or
Media
Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890
bill@gothamcomm.com